CN113527311B - Fgfr4抑制剂、组合物及其在药物制备中的用途 - Google Patents

Fgfr4抑制剂、组合物及其在药物制备中的用途 Download PDF

Info

Publication number
CN113527311B
CN113527311B CN202110965475.4A CN202110965475A CN113527311B CN 113527311 B CN113527311 B CN 113527311B CN 202110965475 A CN202110965475 A CN 202110965475A CN 113527311 B CN113527311 B CN 113527311B
Authority
CN
China
Prior art keywords
cancer
fgfr4
compound
reaction
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110965475.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113527311A (zh
Inventor
陈永恒
陈小娟
徐广宇
付莹
陈主初
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiangya Hospital of Central South University
Original Assignee
Xiangya Hospital of Central South University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiangya Hospital of Central South University filed Critical Xiangya Hospital of Central South University
Priority to CN202110965475.4A priority Critical patent/CN113527311B/zh
Publication of CN113527311A publication Critical patent/CN113527311A/zh
Priority to PCT/CN2022/088850 priority patent/WO2023024545A1/fr
Application granted granted Critical
Publication of CN113527311B publication Critical patent/CN113527311B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202110965475.4A 2021-08-23 2021-08-23 Fgfr4抑制剂、组合物及其在药物制备中的用途 Active CN113527311B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202110965475.4A CN113527311B (zh) 2021-08-23 2021-08-23 Fgfr4抑制剂、组合物及其在药物制备中的用途
PCT/CN2022/088850 WO2023024545A1 (fr) 2021-08-23 2022-04-24 Inhibiteur de fgfr4 et composition, et leurs utilisations pour la préparation d'un médicament

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110965475.4A CN113527311B (zh) 2021-08-23 2021-08-23 Fgfr4抑制剂、组合物及其在药物制备中的用途

Publications (2)

Publication Number Publication Date
CN113527311A CN113527311A (zh) 2021-10-22
CN113527311B true CN113527311B (zh) 2022-05-06

Family

ID=78122728

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110965475.4A Active CN113527311B (zh) 2021-08-23 2021-08-23 Fgfr4抑制剂、组合物及其在药物制备中的用途

Country Status (2)

Country Link
CN (1) CN113527311B (fr)
WO (1) WO2023024545A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113527311B (zh) * 2021-08-23 2022-05-06 中南大学湘雅医院 Fgfr4抑制剂、组合物及其在药物制备中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109384790A (zh) * 2017-08-08 2019-02-26 南京药捷安康生物科技有限公司 成纤维细胞生长因子受体抑制剂及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014228746B2 (en) * 2013-03-15 2018-08-30 Celgene Car Llc Heteroaryl compounds and uses thereof
TWI649318B (zh) * 2013-04-19 2019-02-01 英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
CN111689959B (zh) * 2016-05-27 2022-04-01 石药集团中奇制药技术（石家庄）有限公司 作为fgfr4抑制剂的杂环化合物
RU2747260C2 (ru) * 2016-12-19 2021-04-29 Аббиско Тхерапеутицс Цо., Лтд. Ингибитор рфрф4, способ его получения и его фармацевтическое применение
CN111138459B (zh) * 2018-11-06 2022-10-18 南京圣和药业股份有限公司 Fgfr4抑制剂的光学异构体及其应用
CN113527311B (zh) * 2021-08-23 2022-05-06 中南大学湘雅医院 Fgfr4抑制剂、组合物及其在药物制备中的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109384790A (zh) * 2017-08-08 2019-02-26 南京药捷安康生物科技有限公司 成纤维细胞生长因子受体抑制剂及其用途

Also Published As

Publication number Publication date
CN113527311A (zh) 2021-10-22
WO2023024545A1 (fr) 2023-03-02

Similar Documents

Publication Publication Date Title
CN113544128A (zh) Kras-g12c抑制剂
KR101828187B1 (ko) 신규 축합 피리미딘 화합물 또는 그 염
CN103237799B (zh) 杂环衍生物、制备方法及其药学用途
EP2944639B1 (fr) Composition pour l'inhibition de la progression mitotique
US20210277004A1 (en) Naphthyridinone compounds useful as t cell activators
JP2023528903A (ja) Ｋｒａｓ ｇ１２ｃタンパク質阻害剤およびその使用
KR20180105161A (ko) Egfr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제
EP3312180B1 (fr) Utilisation de dérivés de ptéridinone en tant qu'inhibiteur de l'egfr
KR20190099209A (ko) 8,9-디하이드로이미다졸[1,2-a]피리미도[5,4-e]피리미딘-5(6H)-케톤계 화합물
RU2763328C2 (ru) Кристаллический ингибитор fgfr4 и его применение
WO2018192536A1 (fr) Composé pyrimido-hétérocyclique servant d'inhibiteur de la tyrosine kinase de bruton et ses applications
WO2019034128A1 (fr) Dérivé de pyrrolotriazine, son procédé de préparation et son utilisation
CN101119996A (zh) 化学化合物
CN112771049B (zh) Fgfr4抑制剂及其应用
WO2022188819A1 (fr) Modulateur de protéolyse sos1, son procédé de préparation et son application
CN116528868A (zh) 三环kras g12c抑制剂
EP3476846A1 (fr) Nouveau dérivé hétérocyclique et son utilisation
EP2928466B1 (fr) Utilisation de dérivés de maléimide pour la prévention et le traitement de la leucémie
WO2015058661A1 (fr) Inhibiteur de bcr-abl kinase et application correspondante
KR20190021345A (ko) Egfr 저해제로 제공되는 아닐린 피리미딘 화합물의 결정
CN107207504A (zh) 酞嗪酮衍生物、其制备方法及用途
CN113527311B (zh) Fgfr4抑制剂、组合物及其在药物制备中的用途
AU2017364720A1 (en) Novel oxoisoquinoline derivative
EP3865488A1 (fr) Composé macrocyclique servant d'inhibiteur de cdk, son procédé de préparation et son utilisation en médecine
EP3750893B1 (fr) Composé de dioxazoline, son procédé de préparation et ses applications

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant